tbuckley/cabot-search huggingface dataset:
THU0495 Oxidized Low Density Lipoproteins and Efficacy of Osteoarthritis Therapy with Avocado and Soya Unsaponifiables
Authors: Y. Akhverdyan, B. Zavodovsky, J. Polyakova, L. Seewordova, A. Zborovsky
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Oxidized low density lipoproteins (o-LDLP) are essential for progression of metabolic syndrome and development of its clinical manifestations. There are some data than o-LDLP are important in the pathogenesis of osteoarthritis (OA) through apoptosis of chondrocytes. Experiments in rat articular chondrocytes culture showed that o-LDLP may cause death of this cells. Avocado and soya unsaponifiables (ASU) is common medicine in OA. We suppose ASU may influence on lipid metabolism and their efficiency may be connected with o-LDLP level in OA. <h3>Objectives</h3> To study serum o-LDLP concentration in OA and to improve results of ASU therapy in OA patients depending on the o-LDLP level in serum. <h3>Methods</h3> We examined 175 people: 130 OA patients and 45 healthy donors. The patients receiving ASU (Piascledin, Expanscience, France, n=40) 300 mg per day for 3 months were divided into 2 groups: The first (1-st) group (24 OA patients) had increased o-LDLP level (more than 168 ng/ml). The second (2-nd) group (16 patients) had normal o-LDLP level. The level o-LDLP were determined with ELISA- test (Biomedica Gruppe, Oxidized LDL, cat No. 20042) before and after treatment. <h3>Results</h3> o-LDLP concentration in serum of healthy individuals was 114,3±4,2 ng/ml (here and further M±m). The level of normal o-LDLP values defined as M±2 standard deviation was from 60 to 168 ng/ml. Elevated o-LDLP levels in OA patients sera was detected in 78 (60%) (difference with healthy subjects, p&lt;0,001). o-LDLP concentration in OA patients was 252.2+3.4 ng/ml (difference with healthy subjects =0.0014). After ASU therapy we revealed improvement of the functional status in OA patients. ASU treatment resulted in decreasing of o-LDLP level (p&lt;0,01) and C reactive protein concentration (p&lt;0,01) in serum. In this study we determined improvement of a condition in 95.83% of patients in 1-st subgroup, and in only 50.0% in 2-nd subgroup. <h3>Conclusions</h3> Thus, we noted increased o-LDLP level in OA patients. Elevated o-LDLP level was detected in 60.0% of patients that were significantly more than that of healthy individuals (4.4%). Efficacy of ASU therapy in OA depends on the initial level of o-LDLP in serum. ASU are more effective at the level of serum o-LDLP more than 168 ng/ml. Hence, determination of o-LDLP in OA patients may increase ASU efficiency. <h3>Disclosure of Interest</h3> None declared
Lipemia Retinalis
Authors: H L Fred, M Accad
Journal: New England Journal of Medicine (1999)

Figure 1 A 36-year-old woman with newly discovered diabetes mellitus had eruptive xanthomata on her elbows and knees together with striking retinal changes. Her vision was normal, but all retinal vessels appeared creamy white, and the veins were distinguishable from arteries only by their larger caliber (Panel A). This funduscopic finding occurs only with extreme hypertriglyceridemia — concentrations of triglycerides generally exceed 4000 mg per deciliter (45.2 mmol per liter). A blood specimen was lipemic (Panel B), with a triglyceride concentration of 21,040 mg per deciliter (237.5 mmol per liter; normal range, 10 to 190 [0.11 to 2.15 mmol per liter]). The patient was treated with insulin and a low-fat diet, and by the seventh day of treatment, her triglyceride concentration had fallen to 2192 mg per deciliter (24.7 mmol per liter) and the retinas appeared normal. Figure 1 A 36-year-old woman with newly discovered diabetes mellitus had eruptive xanthomata on her elbows and knees together with striking retinal changes. Her vision was normal, but all retinal vessels appeared creamy white, and the veins were distinguishable from arteries only by their larger caliber (Panel A). This funduscopic finding occurs only with extreme hypertriglyceridemia — concentrations of triglycerides generally exceed 4000 mg per deciliter (45.2 mmol per liter). A blood specimen was lipemic (Panel B), with a triglyceride concentration of 21,040 mg per deciliter (237.5 mmol per liter; normal range, 10 to 190 [0.11 to 2.15 mmol per liter]). The patient was treated with insulin and a low-fat diet, and by the seventh day of treatment, her triglyceride concentration had fallen to 2192 mg per deciliter (24.7 mmol per liter) and the retinas appeared normal. Herbert L. Fred, M.D.Michel Accad, M.D.University of Texas Health Science Center, Houston, TX 77030
Restrospective analysis of non-Hodgkin lymphoma (NHL) patients (p) treated with <sup>90</sup>Y ibritumomab tiuxetan (90Y- IT): Iberia RIT database
Authors: P. Giraldo, J. Gómez Codina, M. Provencio, T. Hernando, J. L. Tisaire
Journal: Journal of Clinical Oncology (2007)

18526 Background: 90Y-IT is approved for the treatment of refractory NHL. The aim of this study was to collect data of NHL p treated with 90Y-IT within the clinical practice setting, to retrospectively analyze treatment effectiveness and tolerability, in order to provide a pragmatic approach to experimental data. Methods: Multicenter, retrospective study. NHL p treated during last year with 90Y-IT, were registered. Effectiveness endpoints retrospectively studied were: objective response rate (ORR), time to progression (TTP) and overall survival (OS). Clinical prognostic factors were collected to asses their possible influence upon treatment effectiveness, by multivariate analyses. Results: 65 p were registered: M/F, 58.5%/41.5%; median age, 59 years (22–83); ECOG 0–1, 73.3%. Median time since lymphoma diagnosis was 3.6 years. At diagnosis, 84.6% had follicular lymphoma (grade 1, 44.9%; grade 2, 40.8%) and 15.4% non- follicular lymphoma. Most of the cases were refractory to previous treatments (78.1%). Median number of previous treatments was 3 (range 1–8) Median administered dose of 90Y-IT was 0.4 mCi/Kg. ORR was 70.8% (95% CI: 59.8, 81.9). With a median follow-up time of 6 months, median TTP was 16.1 months (95% CI: 11.2, 21.1) and median OS has not been achieved. Within the group of follicular lymphoma, ORR was 74.6% (95% CI: 63.1–86.1) and TTP 17.7 months (95% CI: 14.3, 21.1). Bone marrow involvement and high FLIPI score were significantly associated with higher risk of progression disease: hazard ratio 3.71 (95% CI: 1.00, 13.68) and 21.12 (95% CI: 2.37, 187.91), respectively. Median time to G3–4 haematological toxicity ranged between 27–38.5 days, being the most frequent thrombocitopenia (46.2%) and neutropenia (33.8%). 17 p required red blood cell transfusions (median, 4 U) and 19 required platelet transfusions (median, 7 U). The most frequent G3–4 non haematological toxicity was asthenia (10.8%). Updated survival data will be presented at the meeting. Conclusions: These results obtained with 90Y-IT for NHL treatment within the clinical practice setting are concordant with published experimental data, despite the limitations of the retrospective design. [Table: see text]
A novel approach to the management of polypectomy snare entrapment: the zip-line technique
Authors: Robert Herman, Michael Herman, Carline Etienne, Sharareh Kavosh, Pavanaja Reddy
Journal: Endoscopy (2015)

Polypectomy-snare entrapment is a rare but serious complication of colonoscopy, frequently requiring surgical intervention. We report a case of polypectomy-snare entrapment successfully treated using a novel endoscopic "zip-line" approach that, to our knowledge, has not been previously reported.
Cytotoxic Antibodies in the Homograft Reaction
Authors: Leo Sachs, Michael Feldman
Journal: JNCI Journal of the National Cancer Institute (1958)

An analysis was made of the cytotoxic isoantibodies that can be demonstrated in vitro by the addition of complement, using, mainly, the strain specific tumors 6C3HED and DBA, and the homotransplantable MC1M, MC1A, 6C3HED-ICR and DBA-ICR. Homografts of the strain-specific tumors can elicit production of the cytotoxic antibodies. The cytotoxins produced by 6C3HED are effective against 6C3HED but not against MC1M, though homografts of MC1M and of normal C3H tissues can elicit cytotoxins active against both MC1M and 6C3HED. Cells of 6C3HED therefore possess one toxinogen, C′, shared by MC1M and normal C3H tissues, whereas the latter possess a second toxinogen, M′, which is not present in 6C3HED. This was confirmed by absorptive experiments. Homografts of MC1A, 6C3HED-ICR, and DBA-ICR, did not elicit production of the cytotoxic antibodies. These tumors were also not affected by the cytotoxins produced by 6C3HED, MC1M, or DBA. DBA-ICR lost the toxinogens of DBA. Cells of MC1A and 6C3HED-ICR lost the C′ antigen of 6C3HED and the M′ of MC1M. In vitro absorption tests demonstrated that MC1A possesses a nontoxinogenic antigen, A′, that is related to an MC1M toxinogen. MC1M has the antigenic constitution, C′, M′, A′, with C′ and A′ forming a complex antigen that produces a complex antibody molecule. It was shown that in the absence of added complement, these cytotoxic antibodies do not produce a destruction of the tumor cells in vivo. Thus they seem to play no direct role in the homograft reaction.
Effect of beta-blocking agents and angiotensin II on isoproterenol-stimulated renin release from rat kidney slices.
Authors: Capponi Am, Gourjon M, Vallotton Mb
Journal: Circulation Research (1977)

UNLABELLED Mechanisms by which beta-blocking agents decrease blood pressure and suppress renin release are incompletely understood. We previously demonstrated that renin release by kidney slices may be increased by beta-adrenergic agonists, and the present communication contains our results on the effects of 15 beta-blocking agents and angiotensin II on isoproterenol-stimulated renin release. None of the beta-blocking compounds inhibited basal renin release. Each agent was evaluated at concentrations ranging from 10-8 to 10-5 m and three different dose-response curve patterns were observed: (1) Metoprolol, acebutolol, labetalol, and d-propranolol had no effect on isoproterenol-stimulated renin release at any concentration, whereas pindolol and bufuralol demonstrated minimal inhibition at 10-5 m only. (2) Isoproterenol stimulation was completely inhibited when dl- or l-propranolol, alprenolol, and sotalol were administered at doses ranging between 5 x 10-6 and 10-6 m; but greater concentration of these agents resulted in reappearance of the isoproterenol response. (3) Dose-related inhibition was observed with practolol, oxprenolol, timolol, nadolol, and atenolol at concentrations ranging from 10-8 to 10-5 m. Basal renin release was significantly (P is less than 0.01) inhibited by angiotensin II at 10-6 m, which also inhibited isoproterenol-stimulated renin release in a dose-related fashion. [Sar1, Ala8] angiotensin II had no direct effects on either basal or isoproterenol-stimulated renin release, but blocked the inhibitory action of angiotensin II on these parameters. CONCLUSIONS There are three different effects of beta-blocking agents on isoproterenol-stimulated renin release which can only partially be explained by their presently ascribed pharmacological properties. (Beta 1- and beta2-agonists, intrinsic sympathomimetic activity, membrane-stabilizing actions). Angiotensin II inhibition of renin release appears to be functionally related to adrenergic pathways.
FRI0054 Comparison of Patients with Rheumatoid Arthritis on Disease Remission in Europe and United States
Authors: S. Narayanan, Y. Lu, R. Hutchings, A. Baskett
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Disease remission is a critical milestone in management of Rheumatoid Arthritis (RA). Both the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) have been working on refining the definition of remission in RA over the last several years; the influence of these efforts on physician practices in terms of consistency in definition of remission (as depicted by characteristics of patients identified to be in remission) within Europe (EU) and between EU and the United States (US) has not been evaluated. <h3>Objectives</h3> To compare RA patients on disease remission in the EU and US among those receiving a biologic treatment as part of usual care. <h3>Methods</h3> A multi-country multi-center medical chart-review study of RA patients was conducted in 4Q2011 among physicians (majority: rheumatologists) in hospitals/private practices to collect de-identified data on patients who were recently treated with a biologic as part of usual care. Physicians were screened for practice-duration and patient-volume and recruited from a large panel to be geographically representative in the EU (UK/Germany/France/Italy/Spain) and US. For each study-eligible patient chart, physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status (incl. assessment of “disease remission”, per physician clinical judgment (both objective &amp; subjective)). Patients on disease remission were analyzed. <h3>Results</h3> Analysis included 1161 and 405 patients experiencing disease remission in the EU and US respectively; 75% (vs. 74%), 20% (vs. 22%) and 5% (vs. 4%) were on 1st line, 2nd line and ≥3rd line biologic respectively in the EU (vs. US). Mean duration in remission was: EU-12.2mo vs. US-12.1mo. Among those with lab measures, results were mostly similar between patients in remission in the EUvs.US: mean ESR (mm/h): 17.0 vs. 18.9, mean CRP (mg/dl): 7.0 vs. 1.6, Rheumatoid Factor (% positive): 83%vs.87% and Anti-CCP (% positive): 75%vs.74%. Among those with available data, recent (mean) disease severity scores were also similar between patients in remission in the EUvs.US: Tender Joint Count: 2.3 vs. 1.7, Swollen Joint Count: 1.2 vs. 0.8, 100mm VAS score: 18.6 vs. 18.9, HAQ: 0.7 vs. 0.6 and DAS28: 2.6 vs. 2.2. <h3>Conclusions</h3> This is one of the first studies to compare RA patients in remission in the EU and US; the characteristics of these RA patients in remission were found mostly similar between these geographic clusters, despite the potential variations in healthcare systems and modalities of care delivery, possibly attributed by ACR/EULAR efforts in standardizing the outcome definitions and care delivery over the years. <h3>Disclosure of Interest</h3> S. Narayanan Employee of: Ipsos, Y. Lu Employee of: Ipsos, R. Hutchings Employee of: Ipsos, A. Baskett Employee of: Ipsos
PTH-223 Evaluation of bioelectrical impedance testing in hospital in-patients
Authors: E Player, A Forbes
Journal: Gut (2015)

<h3>Introduction</h3> Assessment of nutritional status in the clinical setting is difficult and often poorly achieved. Bioelectrical impedance analysis (BIA)-derived phase angle (PA) is a simple and non-invasive tool which refines the determination of nutritional status, reflects body cell health, and has prognostic value. However BIA is not much used in clinical practice because of protocols which oblige the patient to be starved and on bed-rest. The research underpinning these protocols is dated and insecure; thus the restrictions may not be necessary. <h3>Method</h3> <h3>Aim</h3> To determine whether eating and exercise affect BIA-derived Phase Angle. <h3>Methods</h3> BIA measurements (Bodystat Quadscan 4000) were made on 17 in-patients who were starved and rested. It was then repeated on two occasions: following exertion and after eating breakfast. Inclusion Criteria – Adult in-patients with capacity to consent. Exclusion Criteria – Nil by mouth, pregnancy, too unwell or otherwise unable to exercise. Statistical analysis SPSS: Wilcoxon signed-rank test for non-parametric data. <h3>Results</h3> PA measurements were typical of a hospital patient cohort. Neither exercise nor eating made a statistically nor clinically significant difference to the PA mean PA= 4.312, mean PA= 4.376, (pre-exercise and food vs. post-exercise: p = 0.057), mean PA= 4.335 (pre-exercise and food vs. after food: p = 0.651) <h3>Conclusion</h3> In summary, the current protocols of starving and resting patients appear unnecessary and outdated (with due recognition of our small sample size). It is probable that PA measurement is a practical means to improve assessment of nutritional status in hospitalised patients. <h3>Disclosure of interest</h3> None Declared.
Essentials of filoviral load quantification
Authors: Lieselotte Cnops, Johan van Griensven, Anna N Honko, Daniel G Bausch, Armand Sprecher, Charles E Hill, Robert Colebunders, Joshua C Johnson, Anthony Griffiths, Gustavo F Palacios, Colleen S Kraft, Gary Kobinger, Angela Hewlett, David A Norwood, Pardis Sabeti, Peter B Jahrling, Pierre Formenty, Jens H Kuhn, Kevin K Ariën
Journal: The Lancet Infectious Diseases (2016)
Leukotriene Antagonists in Asthma
Authors: Brian Lipworth, Catherine Jackson
Journal: New England Journal of Medicine (2011)

Aim Cysteinyl leukotrienes are important pro-inflammatory mediators in the pathogenesis of asthma, while leukotriene C 4 synthase is a key enzyme in their biosynthesis. Our aim is to evaluate whether responsiveness to leukotriene receptor antagonists was determined by expression of the variant (C) or wild-type (A) polymorphism of this enzyme. Methods We carried out a retrospective analysis of 8 randomised, placebo-controlled trials performed in our department in mild-to-moderate asthmatics. In all trials, effect of leukotriene receptor antagonist was compared to placebo, where the primary outcome was bronchial hyperresponsiveness to adenosine monophosphate or methacholine. Secondary outcomes were forced expiratory volume in 1 second, exhaled nitric oxide and peripheral blood eosinophils . Results For the primary outcome of attenuation of bronchial hyperresponsiveness by leukotriene receptor antagonist vs placebo, there were significant effects within each genotype on adenosine monophosphate (AMP) ( n = 78): 2.21 and 2.07-fold improvements for AA and AC/CC, respectively; while for methacholine (n = 81) there were 1.39 and 1.36-fold improvements, respectively. There were no significant differences between genotypes (i.e. AA vs AC/CC): geometric mean fold-differences of 1.07 (95%CI 0.63–1.81) and 1.02 (95%CI 0.70–1.50) for AMP and methacholine, respectively. There were also no differences between genotypes for all secondary outcomes. Conclusion Polymorphisms of leukotriene C 4 synthase did not determine responsiveness, in terms of attenuation of bronchial hyperresponsiveness, to leukotriene receptor antagonists in mild-to-moderate asthmatics. Further prospective large pharmacogenetic studies are required in more severe patients, where there may be greater improvements in pharmacodynamic outcome measures such as bronchial hyperresponsiveness and exhaled nitric oxide.
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic carcinoma
Authors: E. Espinosa, J. Feliu, J. de Castro, C. Belda, E. Casado, A. Herrero, M. Sereno, A. Pinto, C. Gomez, M. Gonzalez Baron
Journal: Journal of Clinical Oncology (2007)

15013 Background: The efficacy of gemcitabine in pancreatic cancer can be improved by its combination with erlotinib. Likewise, a fixed dose-rate infusion of gemcitabine seems to be superior to the conventional 30-minute infusion. Our objective was to evaluate the efficacy and toxicity of a fixed dose-rate infusion of gemcitabine associated with erlotinib in patients with advanced adenocarcinoma of the pancreas. Methods: From May 2005 to October 2006, 21 chemotherapy-naïve patients were included, median age 62 years (range 47 - 78), male/female 12/9. Five patients (24%) had locally advanced disease and 16 (76%) distant metastases. The Karnofsky score was 80–100 in 11 (52%), and 60–70 in 10 (48%). Treatment consisted of gemcitabine 1200 mg/m2 given as a 120-minute infusion on days 1, 8, 15, plus erlotinib 100 mg p.o daily. Cycles were repeated every 4 weeks. Results: A total of 80 cycles of chemotherapy were delivered with a median of 3.8 per patient (range 1- 8). There were five partial responses (24%, 95% CI: 8.4 - 47.6%), whereas seven patients had stable disease (33%) and 9 had a progression (43%). The median time to progression was 4 months. After a median follow-up of 6 months (1–14 months), the median overall survival has not been achieved. Toxicity was low. Grade 3- 4 WHO toxicities per patient were as follows: neutropenia in 5 (24%), thrombocytopenia in 1 (5%) and anaemia in 3 (14%). Grade 1–2 rash appeared in 8 (38%) and grade 3 in 3 (14%). Four patients (19%) had diarrhoea grade 1–2. Conclusions: These preliminary results suggest that a fixed dose-rate infusion of gemcitabine associated with erlotinib is active and well tolerated in patients with advanced pancreatic carcinoma. No significant financial relationships to disclose.
Eclampsia-Like Condition in Pregnant Rats Injected with Progesterone&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Symeonidis, Alexander
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article Eclampsia-Like Condition in Pregnant Rats Injected with Progesterone Get access Alexander Symeonidis Alexander Symeonidis Pathology Section, National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 3, December 1949, Pages 711–718, https://doi.org/10.1093/jnci/10.3.711 Published: 01 December 1949 Article history Received: 15 October 1949 Published: 01 December 1949